The International Neuroendocrine Cancer Alliance (INCA) calls for equal access to treatments and care for all neuroendocrine cancer patients globally, regardless of how much money they have or where they live. Ministries and healthcare institutions need to ensure that all neuroendocrine tumor treatments and healthcare services are available and accessible to everyone.
You can download the infographics capturing the challenges with access to NET treatment and care in 10 languages below.
The results from SCAN show a huge difference in the availability of most used neuroendocrine tumor (NET) treatments and healthcare services around the world:
- NET patients often have to travel over 250 km just to see a specialist.
- Less than a third of NET patients globally use multidisciplinary team care, which is essential for a complicated disease such as NET.
- Patients living in emerging and developing economies (EDE) are at an even greater disadvantage to access specialists. Services such as psychological support virtually do not exist.
- Somatostatin analogs are available to only 67% of patients living in countries with advanced economies (AE) and 59% of patients in emerging and developing economies (EDE).
- Peptide receptor radionuclide therapy (PRRT) is available to 57% of AE patients and to only 33% of EDE patients.
All NET patients need better and more inclusive healthcare plans and evidence-based policies for NETs.
The neuroendocrine cancer community around the world joins efforts to drive change and help improve patient outcomes. Join us and support our Equal Access to Treatments and Care for All Patients campaign this April 2021.
Follow @NETCancerDay on social media and help us drive change. We can only do it together!